Recommendations for diagnosis and management of multiple sclerosis

Acta Clinica Croatica

Volumn 51, Issue 1, 2012, Pages 117-135

  Kes, Vanja Bašić ^a   Zavoreo, Iris ^a   Šerić, Vesna ^a   Solter, Vesna Vargek ^a   Cesarik, Marijan ^b   Hajnšek, Sanja ^c   Pašić, Marija Bošnjak ^c   Gabelić, Tereza ^c   Bašić, Silvio ^d   Butković, Silva Soldo ^e   Lušić, Ivo ^f   Grbelja, Lidija Dežmalj ^a   Vladić, Ante ^g   Bielen, Ivan ^g   Antončić, Igor ^h   Demarin, Vida ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b Po ega General Hospital   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d University of Zagreb   (Croatia)

^e JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

^f UNIVERSITY HOSPITAL SPLIT   (Croatia)

^g University Hospital Sveti Duh   (Croatia)

^h KBC RIJEKA   (Croatia)

Author keywords

Diagnostic criteria; Multiple sclerosis clinical evaluation; Treatment

Indexed keywords

ALEMTUZUMAB; AMANTADINE; AMITRIPTYLINE; AZATHIOPRINE; BACLOFEN; BETA1A INTERFERON; BOTULINUM TOXIN; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; DIAZEPAM; FINGOLIMOD; GABAPENTIN; GLATIRAMER; IFOSFAMIDE; IMMUNOGLOBULIN; INTERFERON BETA SERINE; LAMOTRIGINE; METHYLPREDNISOLONE; MITOXANTRONE; MODAFINIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; OXYBUTYNIN; PEMOLINE; PLACEBO; PREGABALIN; TIZANIDINE; TOLTERODINE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; AGE DISTRIBUTION; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EVALUATION; DEMYELINATING DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; EVOKED RESPONSE; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; GOOD CLINICAL PRACTICE; HEMORRHAGIC CYSTITIS; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NEUROLOGIST; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRACTICE GUIDELINE; RADIODIAGNOSIS; RADIOLOGICAL ISOLATED SYNDROME; RECURRENT DISSEMINATED ENCEPHALOMYELITIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIPLE SCLEROSIS;

EID: 84868657276     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
2. Benedict R, Cox D, Thompson L, Foley F, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler 2004;10:675-8.
3. Rojas JI, Patrucco L, Cristiano E. Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis. J Neurol 2010;257:1188-91.
4. Tintore M, Rovira A, Rio J, Tur C, Pelayo R, Nos C, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 2008;70:1079-83.
5. Filippi M, Rocca MA, Arnold DL, Bakshi R, Barkhof F, De Stefano N, et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol 2006;13:313-25.
6. Rovira A, Tintore M, Alvarez-Cermen OJC, Izquierdo G, Prieto JM. Recommendations for using and interpreting magnetic resonance imaging in multiple sclerosis. Neurologia 2010;25:248-65.
7. Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers Consensus guidelines. AJNR Am J Neuroradiol 2006;27:455-61.
8. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
9. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-7.
10. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005;58:840-6.
11. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
12. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galleta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman Ch. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-74.
13. Montalban X, Tintore M, Swanton J, Barkhof F, Filippi M, Frederiksen J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010;74:427-34.
14. Swanton JK, Fernando K, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, et al. Modification of MRI criteria for MS in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006;77:830-3.
15. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72:800-5.
16. Karusis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, Freedman M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Miller A. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2006;13:61-71.
17. Canadian MS Working Group. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004;31:157-68.
18. International Working Group for Treatment Optimization in MS. Treatment optimization in multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2004;11:43-7.
19. Durelli L, Cocito D, Riccio A. High dose intravenous methylprednisolone in the treatment of multiple sclerosis. Neurology 1986;36:238-43.
20. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al., BEYOND Study Group. 250 mg or 500 mg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-97.
21. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14.
22. IFN-beta Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993;43:655-61.
23. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
24. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97.
25. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97.
26. PRISMS Study Group. Randomised double blind placebocontrolled study of interferon beta-1a in relapsing/remitting multiple sclerosis PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneous in Multiple Sclerosis) Study Group. Lancet 1998;359:1498-504.
27. Cadavid D, Wolanksky LJ, Skurnick J, Lincoln J, Cheriyan K, Szczepanowski K, et al. Efficacy of treatment of MS with IFNb-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-83.
28. Goodin DS, Hurwitz B, Noronha A. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007;35:173-87.
29. Rieckmann P, Traboulsee A, Devonshire V, Oger J. Escalating immunotherapy of multiple sclerosis: further options for escalating immunotherapy. Ther Adv Neurol Disord 2008;1:181-92.
30. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri B, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
31. Kappos L, Radue EW, O'Connor P, Polman C, Holfeld R, Calabresi P, et al. A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
32. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
33. Wynn D, Kaufman M, Montalban X, Wollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add on trial with interferon beta. Lancet Neurol 2010;9:381-90.
34. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63:395-400.
35. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
36. Havrdova E, Galleta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of natalizumab safety and efficacy in relapsing remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 2009;8:254-60.
37. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81.
38. Krishnan C, Kaplin AI, Brodsky RA, Drach-Man DB, Jones RJ, Pham DL, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008;65:1044-51.
39. Hartung HP. Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double blind, randomised, multicentre trial. Lancet 2002;360:2018-25.
40. Edan G. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:12-8.
41. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82.
42. Melo A, Rodrigues B, Bar-Or A. Beta interferons in clinically isolated syndromes: a meta-analysis. Arq Neuropsiquiatr 2008;66:8-10.
43. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9.
44. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11.
45. Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Eur Neurol 2006;56:78-105.